Brokerages Set GRAIL, Inc. (NASDAQ:GRAL) Price Target at $67.78

GRAIL, Inc. (NASDAQ:GRAL) has been given a consensus rating of “Hold” by the ten analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $67.7778.

Several brokerages recently weighed in on GRAL. Piper Sandler lifted their price target on GRAIL from $54.00 to $56.00 and gave the company a “neutral” rating in a research report on Wednesday, May 6th. TD Cowen restated a “buy” rating on shares of GRAIL in a research report on Wednesday, July 15th. Mizuho lifted their target price on shares of GRAIL from $58.00 to $65.00 and gave the company a “neutral” rating in a report on Wednesday, July 15th. Wolfe Research began coverage on shares of GRAIL in a report on Tuesday, June 2nd. They set a “peer perform” rating for the company. Finally, Robert W. Baird set a $70.00 target price on shares of GRAIL in a research note on Wednesday, May 6th.

Insiders Place Their Bets

In other GRAIL news, insider Andrew John Partridge sold 1,491 shares of GRAIL stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $61.08, for a total value of $91,070.28. Following the completion of the transaction, the insider owned 163,738 shares of the company’s stock, valued at approximately $10,001,117.04. The trade was a 0.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.83% of the company’s stock.

Institutional Investors Weigh In On GRAIL

A number of institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. grew its holdings in GRAIL by 159.1% in the third quarter. JPMorgan Chase & Co. now owns 206,120 shares of the company’s stock valued at $12,188,000 after purchasing an additional 126,576 shares during the period. Northwestern Mutual Wealth Management Co. increased its position in shares of GRAIL by 154,361.0% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 91,132 shares of the company’s stock valued at $7,531,000 after buying an additional 91,073 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of GRAIL by 9.0% during the 4th quarter. Vanguard Group Inc. now owns 1,980,783 shares of the company’s stock worth $169,535,000 after buying an additional 163,790 shares during the period. WIM INVESTMENT MANAGEMENT Ltd raised its stake in shares of GRAIL by 68.9% during the 4th quarter. WIM INVESTMENT MANAGEMENT Ltd now owns 106,400 shares of the company’s stock worth $9,107,000 after buying an additional 43,400 shares during the period. Finally, Pictet Asset Management Holding SA lifted its position in shares of GRAIL by 1,036.8% during the 4th quarter. Pictet Asset Management Holding SA now owns 40,926 shares of the company’s stock valued at $3,585,000 after buying an additional 37,326 shares in the last quarter.

GRAIL Stock Performance

NASDAQ GRAL opened at $72.71 on Friday. The stock has a 50-day simple moving average of $66.01 and a two-hundred day simple moving average of $69.01. The firm has a market capitalization of $3.12 billion, a P/E ratio of -7.01 and a beta of 3.22. GRAIL has a fifty-two week low of $29.95 and a fifty-two week high of $118.84.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($2.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.76) by $0.47. GRAIL had a negative return on equity of 16.42% and a negative net margin of 253.22%.The business had revenue of $40.78 million during the quarter, compared to analysts’ expectations of $39.16 million. As a group, analysts forecast that GRAIL will post -10.91 earnings per share for the current year.

GRAIL News Summary

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: GRAIL stock has been trading higher, helped by a rebound from a prior selloff and continued investor interest following the recent oversold move.
• Neutral Sentiment: Several law firms are reminding shareholders that the August 4, 2026 deadline is approaching to seek lead-plaintiff status in the securities class action.
• Negative Sentiment: The class action alleges GRAIL and certain executives misrepresented the NHS-Galleri trial’s expected performance and results, raising legal and reputational risk. Article Title
• Negative Sentiment: More investor-notice articles from Hagens Berman, Pomerantz, Rosen, Faruqi & Faruqi, and others reinforce that litigation remains active and centered on alleged disclosure failures around the trial. Article Title

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.